The American Journal of Managed Care® (AJMC®) study, “The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness,” published in the June 2026 issue, evaluates how increasing state Medicaid reimbursement rates for psychiatrists influence health care utilization, finding that higher rates subsequently reduce high-cost emergency department visits and inpatient admissions for patients with serious mental illness. Becker's Behavioral Health references these findings to emphasize the economic benefits of such policy changes, highlighting the study's key takeaway that higher psychiatrist Medicaid reimbursement is ultimately linked to a 24% reduction in total health care costs for this patient population.
The AJMC study, “Longer Appointment Duration Reduces Future Missed Appointments in Safety-Net Clinics,” published in the February 2025 issue, demonstrates that scheduling longer primary care appointment durations in safety-net clinics significantly decreases the likelihood of future missed appointments, which could indicate patient satisfaction. MedCity News references these findings to emphasize that health care accessibility depends heavily on operational infrastructure, using the study's data to argue that rural and vulnerable communities require robustly structured care models rather than fragmented, hurried appointments to sustain patient engagement and health.
The article, “Stark Insurance and Racial Disparities Seen in Analysis of National CAR T-Cell Data,” published on AJMC.com, the website of AJMC, analyzes national data to reveal that Black and Hispanic patients are significantly underrepresented among those receiving CAR T-cell therapy, while also showing that patients with public insurance face worse posttreatment outcomes compared with those with private coverage. Becker's Oncology references these findings to highlight how structural inequities impact advanced cancer care, focusing on the study's stark revelation that a patient's insurance type is directly linked to higher rates of in-hospital mortality following CAR T-cell therapy.
